CA Patent

CA2941956C — Pharmaceutical composition for treatment of corneal damage

Assigned to Novaliq GmbH · Expires 2018-09-04 · 8y expired

What this patent protects

The invention provides compositions for the treatment of corneal damage comprising a semifluorinated alkane. They can be administered topically into the eye. The invention further provides kits comprising such compositions.

USPTO Abstract

The invention provides compositions for the treatment of corneal damage comprising a semifluorinated alkane. They can be administered topically into the eye. The invention further provides kits comprising such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
CA2941956C
Jurisdiction
CA
Classification
—
Expires
2018-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.